Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Organogenesis Holdings Inc.NASDAQ: ORGO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $65.19M fell 10.1% year over year, behind the +8.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 34.9% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Selling, general & admin amounted to 57.9% of revenue in FY2025, down 3.2 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $111.87M (-65.7%) for the fiscal year ending Dec 2026, a slowdown from the +10.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $65.19M-34.9% QoQ
- Last fiscal yearDec 2025
- $326.24M+10.8% YoY
- LTMMar 2026
- $318.91M+8.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 326.24M USD
- Year-over-year change
- +10.8%
- 4-year CAGR
- +6.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 326.24M | +10.8% |
| FY2024 | 2024-12-31 | 294.51M | +9.2% |
| FY2023 | 2023-12-31 | 269.75M | -5.0% |
| FY2022 | 2022-12-31 | 283.81M | +13.4% |
| FY2021 | 2021-12-31 | 250.2M | — |
Selling, General & Admin vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.2% is the 4th highest of 11, against a peer median of +2.1%.
- Selling, general & admin amounts to 62.1% of revenue for ORGO, versus a peer median of 44.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.67T USD | +20374087.6% | -55.3% | 4982813.7% | |
| LTM Mar 2026 | $1.74B USD | +43733.9% | +1221.7% | — | |
| LTM Mar 2026 | $318.91M USD | +8.2% | +4.8% | 62.1% | |
| LTM Mar 2026 | $216.13M USD | +3.1% | +15.9% | 71.6% | |
| LTM Mar 2026 | CA$210.35M CAD | -3.8% | +10.0% | 22.4% | |
| LTM Mar 2026 | $180.5M USD | -32.3% | -18.1% | 26.7% | |
| LTM Mar 2026 | $165.91M USD | +1.1% | +15.0% | 39.7% | |
| LTM Feb 2026 | $152.38M USD | +6.1% | +2.8% | 48.6% | |
| LTM Apr 2026 | $135.6M USD | -0.5% | +4.1% | 15.8% | |
| LTM Mar 2026 | $76.67M USD | +0.6% | +17.4% | 120.8% | |
| LTM Mar 2026 | $18.51M USD | +10.2% | +13.1% | — | |
| Peer median (excluding ORGO) | — | +2.1% | +11.6% | 44.1% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M |
| Cost of Revenue | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M |
| Gross Profit | 353.16M | 345.87M | 326.66M | 366.3M | 425.51M |
| Gross Margin | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| Research & Development | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
| Selling, General & Admin | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M |
| Operating Expenses | 280.94M | 323.57M | 314.13M | 367.59M | 369.64M |
| Depreciation & Amortization | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M |
| EBITDA | 87M | 40.32M | 36.03M | 15.76M | 73.91M |
| EBITDA Margin | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% |
| Operating Income | 72.22M | 22.3M | 12.53M | (1.28M) | 55.87M |
| Operating Margin | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 2.28M |
| Interest Expense | 7.24M | 2.01M | 2.19M | 1.54M | 0 |
| Other Income / Expenses | (9.13M) | (2.02M) | (2.13M) | (1.52M) | (8.9M) |
| Income Before Tax | 63.09M | 20.28M | 10.39M | (2.81M) | 46.97M |
| Pre-Tax Margin | 13.5% | 4.5% | 2.4% | -0.6% | 8.3% |
| Income Tax Expense | (31.12M) | 4.75M | 5.45M | (3.67M) | 9.94M |
| Net Income | 94.2M | 15.53M | 4.95M | 861K | 37.03M |
| Net Margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (Basic) | 0.73 | 0.12 | 0.04 | (0.01) | 0.16 |
| EPS (Diluted) | 0.70 | 0.12 | 0.04 | (0.01) | 0.15 |
| Weighted Avg Shares | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M |
| Weighted Avg Shares (Diluted) | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.